SuperworthUltragenyx Pharmaceutical profit margin RARE
Gross, operating and net profit as a share of revenue over the last twelve months, from 2020.
- Net margin, 12 months
- −81.7%
- Operating margin, 12 months
- −73.6%
- Net margin on a year earlier
- +5.6 pts
- Peer median
- 13.3%
Over the twelve months to Jun 30, 2026, Ultragenyx Pharmaceutical kept −81.7% of its revenue as net profit, with an operating margin of −73.6%.
Five years earlier its net margin was −97.8%.
The median for 10 large drugmakers of a similar size is 13.3%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −85.4% | −79.4% | n/a |
| FY2024 | n/a | −95.7% | n/a |
| FY2023 | n/a | n/a | n/a |
| FY2022 | n/a | n/a | n/a |
| FY2021 | n/a | n/a | n/a |
| FY2020 | −68.8% | n/a | n/a |
| FY2019 | n/a | n/a | n/a |
| FY2018 | n/a | n/a | 97.8% |
| FY2017 | n/a | n/a | n/a |
| FY2016 | n/a | n/a | n/a |
| FY2015 | n/a | n/a | n/a |
| FY2014 | n/a | n/a | n/a |
| FY2013 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −81.7% | +5.6 pts | −73.6% | |
| Q1 FY26 | −90.9% | +2.2 pts | −83.7% | |
| Q4 FY25 | −85.4% | n/a | −79.4% | |
| Q3 FY25 | −91.9% | n/a | −86.2% | |
| Q2 FY25 | −87.3% | n/a | −82.7% | |
| Q1 FY25 | −93.0% | n/a | −86.9% | |
| Q4 FY24 | n/a | n/a | −95.7% | |
| Q3 FY24 | n/a | n/a | n/a | |
| Q2 FY24 | n/a | n/a | n/a | |
| Q1 FY24 | n/a | n/a | n/a | |
| Q4 FY23 | n/a | n/a | n/a | |
| Q3 FY23 | n/a | n/a | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Ultragenyx Pharmaceutical's size, closest first, today.
| Company | Profit margin |
|---|---|
| RAREUltragenyx Pharmaceutical | −81.7% |
| PAHCPhibro Animal Health | 6.6% |
| ANABAnaptysbio | n/m |
| PCRXPacira BioSciences | 2.0% |
| ANIPANI Pharmaceuticals | 11.1% |
| OMEROmeros | n/m |
| HRMYHarmony Biosciences | 18.9% |
| AMPHAmphastar Pharmaceuticals | 10.8% |
| PBHPrestige Consumer Healthcare | 15.6% |
| NRIXNurix Therapeutics | 42.0% |
| ABUSArbutus Biopharma | 84.2% |
| Peer median | 13.3% |
Where Ultragenyx Pharmaceutical ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Ultragenyx Pharmaceutical
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.